



In the Claims

Please amend claims 1, 29 to 31, 33 without prejudice, as follows

1. (Four times Amended) A compound of the formula:



wherein,

X is $-O-$, $-S-$, $-NH-$, $[-N(R_2)]$ or $-\overset{|}{N}-R_2$;

R_2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C_3-C_{10}) cycloalkyl, aroyl, (C_2-C_{11}) alkanoyl, and phenylsulfonyl groups;


aryl is as defined hereinafter;

August 27, 2003

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;Y is lower alkoxy when p is 2 and X is -O-;[R₁ is R₂₀, R₂₁ or R₂₂, wherein:R₂₀ is -(CH₂)_n- where] n is 2, 3, 4, or 5;[R₂₁ is-CH₂-CH=CH-CH₂-,-CH₂-C≡C-CH₂-,-CH₂-CH=CH-CH₂-CH₂,-CH₂-CH₂-CH=CH-CH₂-,-CH₂-C≡C-CH₂-CH₂- or-CH₂-CH₂-C≡C-CH₂,

the -CH=CH- bond being cis or trans;

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted by at least one C₁-C₆ linear alkyl group, phenyl group, or


where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂ or halogen, p is as previously defined;]

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl,

aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,]
 $-\text{C}(=\text{O})\text{-alkyl}$, $-\text{C}(=\text{O})\text{-O-alkyl}$, $-\text{C}(=\text{O})\text{-aryl}$, $-\text{C}(=\text{O})\text{-heteroaryl}$, or
 $-\text{CH}(\text{OR}_7)\text{-alkyl}$; $-\text{C}(=\text{W})\text{-alkyl}$, $-\text{C}(=\text{W})\text{-aryl}$, or
 $-\text{C}(=\text{W})\text{-heteroaryl}$;

wherein alkyl is lower alkyl;


aryl is phenyl or



¶ 1

wherein R_5 is hydrogen, lower alkyl, lower alkoxy, hydroxy,
chlorine, fluorine, bromine, iodine, lower
monoalkylamino, [lower dialkylamino,] nitro, cyano,
trifluoromethyl, or trifluoromethoxy;

heteroaryl is



Q_3 is $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, or $-\text{CH}=\text{N}-$;

[W is CH_2 or CHR_8 or $\text{N}-\text{R}_9$;]

R_7 is hydrogen, lower alkyl, or [alkanoyl] acyl;

[R_8 is lower alkyl;

R_9 is hydroxy, alkoxy, or $-\text{NHR}_{10}$; and

R_{10} is hydrogen, lower alkyl, $\text{C}_1\text{-C}_3$ acyl, aryl,
 $-\text{C}(=\text{O})\text{-aryl}$ or $-\text{C}(=\text{O})\text{-heteroaryl}$,

August 27, 2003


where aryl and heteroaryl are as defined above;]
and

m is 1, 2, or 3;

with the exclusion of compounds wherein X is O or S, Y is hydrogen, and R is
hydrogen, $[C_1 = 14 C_4] \underline{C_1-C_4}$ alkyl, chlorine, fluorine, bromine, iodine,
cyano, $C_1 - C_4$ alkoxy, or $-COOR_{23}$ where R_{23} is H or $C_1 - C_4$ alkyl;
with the exclusion of compounds wherein X is $-S-$, $[R_1 \text{ is } R_{20}]$ R is H, and m=1;
[all geometric, optical, and stereoisomers thereof.] or a pharmaceutically acceptable
acid addition salt thereof.

August 27, 2003

29. (Four times Amended) A compound of the formula:



wherein X is $-N-R_2$;


p is 1 [or 2];

Y is hydrogen, Cl, Br, or F[, when p is 1];

[Y is lower alkoxy or halogen when p is 2;]

R₂ is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C₃-C₁₀) cycloalkyl, aroyl, (C₂-C₁₁) [aroyl,] alkanoyl, and phenylsulfonyl groups;

aryl is phenyl or



wherein R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, [lower dialkylamino,] nitro, cyano, trifluoromethyl, or trifluoromethoxy;


n is 2, 3, or 4;

R is hydrogen, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl, [acyl, (C₂-C₁₁) alkanyol,] Cl, F, Br, I, amino, C₁-C₃ mono- or dialkylamino, acylamino, -NO₂, -OCF₃,


August 27, 2003

-CF₃, -C(=O)-alkyl, or -CH(OR₇)-alkyl[,];
alkyl is lower alkyl;
R₇ is hydrogen, lower alkyl, or acyl; and
m is 1, 2, or 3;
or a pharmaceutically acceptable acid addition salt thereof.

30. (Four Times Amended) A pharmaceutical composition, which comprises a compound of the formula:



12



wherein X is $-O-$, $-S-$, $-NH-$, or $-N(R_2)$;

R_2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C_3-C_{10}) cycloalkyl, aroyl, (C_2-C_{11}) alkanoyl, and phenylsulfonyl groups;

wherein aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;


Y is lower alkoxy when p is 2 and X is $-O-$;

August 27, 2003

[R₁ is R₂₀, R₂₁ or R₂₂, wherein:R₂₀ is -(CH₂)_n- where] n is 2, 3, 4, or 5;[R₂₁ is

-CH₂-C=CH-CH₂-,
 -CH₂-C≡C-CH₂-,
 -CH₂-CH=CH-CH₂-CH₂,
 -CH₂-CH₂-CH=CH-CH₂-,
 -CH₂-C≡C-CH₂-CH₂- or
 -CH₂-CH₂-C≡C-CH₂,

the -CH=CH- bond being cis or trans;

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted by at least one C₁-C₆ linear alkyl group, phenyl group, or


where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂,
 -NH₂ or halogen, and p as previously defined;]

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,]
 -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or
 -CH(OR₇)-alkyl[.]; [-C(=W)-alkyl, -C(=W)-aryl, or
 -C(=W)-heteroaryl;]


August 27, 2003

alkyl is lower alkyl;

aryl is phenyl or



where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, [lower dialkylamino,] nitro, cyano, trifluoromethyl, or trifluoromethoxy;

02
heteroaryl isQ₃ is -O-, -S-, -NH-, or -CH=N-;[W is CH₂ or CHR₈ or N-R₉ ;]R₇ is hydrogen, lower alkyl, or [(C₂-C₁₁) alkanoyl] acyl;[R₈ is lower alkyl;R₉ is hydroxy, alkoxy, or -NHR₁₀ ; andR₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above;] and

m is 1, 2, or 3;



with the exclusion of compounds wherein X is O or S, Y is hydrogen, and R is hydrogen, C₁-C₄ alkyl, chlorine, fluorine, bromine, iodine, cyano, C₁ - C₄

August 27, 2003

alkoxy, or $-\text{COOR}_{23}$ where R_{23} is H or $\text{C}_1 - \text{C}_4$ alkyl;
with the exclusion of compounds wherein X is $-\text{S}-$, [R_1 is R_{20} ,] R is H, and m=1;
[all geometric, optical, and stereoisomers thereof,] or a pharmaceutically acceptable
acid addition salt thereof, and a pharmaceutically acceptable carrier therefor.

02

31. (Amended four times) An antipsychotic composition, which comprises a compound of the formula:



wherein

X is -O-, -S-, -NH-, or $-N(R_2)$;

R_2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C_3-C_{10}) cycloalkyl, aroyl, (C_2-C_{11}) alkanoyl, and phenylsulfonyl groups; wherein aryl is as defined hereinafter;

p is 1 or 2;


Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

August 27, 2003

Y is lower alkoxy when p is 2 and X is -O-;[R₁ is R₂₀, R₂₁ or R₂₂, wherein:R₂₀ is -(CH₂)_n- where] n is 2, 3, 4, or 5;[R₂₁ is

-CH₂-CH=CH-CH₂-,
 -CH₂-C≡C-CH₂-,
 -CH₂-CH=CH-CH₂-CH₂,
 -CH₂-CH₂-CH=CH-CH₂-,
 -CH₂-C≡C-CH₂-CH₂- or
 -CH₂-CH₂-C≡C-CH₂,

the -CH=CH- bond being cis or trans;

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted by at least one C₁-C₆ linear alkyl group, phenyl group, orwhere Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂,
 -NH₂ or halogen, a p is as previously defined;]


R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,]
 -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or
 -CH(OR₇)-alkyl[,]; [-C(=W)-alkyl, -C(=W)-aryl, or

August 27, 2003

-C(=W)-heteroaryl;]


alkyl is lower alkyl;

aryl is phenyl or



where R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, [lower dialkylamino,] nitro, cyano, trifluoromethyl, or trifluoromethoxy;

heteroaryl is

Q₃ is -O-, -S-, -NH-, or -CH=N-;[W is CH₂ or CHR₈ or N-R₉ ;]R₇ is hydrogen, lower alkyl, or [(C₂-C₁₁) alkanoyl] acyl;[R₈ is lower alkyl;R₉ is hydroxy, alkoxy, or -NHR₁₀; andR₁₀ is hydrogen, lower alkyl, C₁-C₃ acyl, aryl,

-C(=O)-aryl or -C(=O)-heteroaryl,

where aryl and heteroaryl are as defined above;]

and

m is 1, 2, or 3;

with the exclusion of compounds wherein X is O or S, Y is hydrogen, and R

August 27, 2003



is hydrogen, C₁-C₄ alkyl, chlorine, fluorine, bromine, iodine, cyano, C₁ - C₄ alkoxy, or -COOR₂₃ where R₂₃ is H or C₁ - C₄ alkyl;

with the exclusion of compounds wherein X is -S-, [R₁ is R₂₀,] R is H, and m=1;

0 2 [all geometric, optical, and stereoisomers thereof,] or a pharmaceutically acceptable acid addition salt thereof, in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier therefor.

August 27, 2003

33. (Thrice Amended) An analgesic composition, which comprises a compound of the formula:



wherein,

X is -O-, -S-, -NH-, or $[-N(R_2)]$ $\underline{N(R_2)}$;

R_2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, (C_3 – C_{10}) cycloalkyl, aroyl, (C_2 – C_{11}) alkanoyl, and phenylsulfonyl groups;

wherein aryl is as defined hereinafter;

p is 1 or 2;

Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1;

Y is lower alkoxy when p is 2 and X is -O-;

[R₁ is R₂₀, R₂₁ or R₂₂, wherein:


R₂₀ is -(CH₂)_n- where] n is 2, 3, 4, or 5;

[R₂₁ is

-CH₂-CH=CH-CH₂-,
 -CH₂-C≡C-CH₂-,
 -CH₂-CH=CH-CH₂-CH₂,
 -CH₂-CH₂-CH=CH-CH₂-,
 -CH₂-C≡C-CH₂-CH₂- or
 -CH₂-CH₂-C≡C-CH₂,
 the -CH=CH- bond being cis or trans;

13

R₂₂ is R₂₀ or R₂₁ in which one or more carbon atoms of R₂₀ or R₂₁ are substituted by at least one C₁-C₆ linear alkyl group, phenyl group, or




where Z₁ is lower alkyl, -OH, lower alkoxy, -CF₃, -NO₂, -NH₂ or halogen, and p is as previously defined;]

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, [monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,] -C(=O)-alkyl, -C(=O)-O-alkyl, -C(=O)-aryl, -C(=O)-heteroaryl, or

August 27, 2003

$-\text{CH}(\text{OR}_7)\text{-alkyl}[,]; [\text{-C}(=\text{W})\text{-alkyl, -C}(=\text{W})\text{-aryl, or -C}(=\text{W})\text{-heteroaryl};]$
wherein alkyl is lower alkyl;
 aryl is phenyl or




wherein R₅ is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower

p3

monoalkylamino, [lower dialkylamino,] nitro, cyano, trifluoromethyl, or trifluoromethoxy;

heteroaryl is



wherein Q₃ is $-\text{O}-$, $-\text{S}-$, $-\text{NH}-$, or $-\text{CH}=\text{N}-$;

[W is CH_2 or CHR_8 or $\text{N}-\text{R}_9$;]

R_7 is hydrogen, lower alkyl, or [($\text{C}_2\text{-C}_{11}$) alkanoyl] acyl;

[R_8 is lower alkyl;

R_9 is hydroxy, alkoxy, or $-\text{NHR}_{10}$; and

R_{10} is hydrogen, lower alkyl, $\text{C}_1\text{-C}_3$ acyl, aryl,

$-\text{C}(=\text{O})\text{-aryl}$ or $-\text{C}(=\text{O})\text{-heteroaryl}$,

where aryl and heteroaryl are as defined above;] and

m is 1, 2, or 3;

August 27, 2003

with the exclusion of compounds wherein X is O or S, Y is hydrogen, and R is hydrogen, C₁-C₄ alkyl, chlorine, fluorine, bromine, iodine, cyano, C₁-C₄ alkoxy, or -COOR₂₃

wherein R₂₃ is H or C₁-C₄ alkyl;

03
with the exclusion of compounds wherein X is -S-, [R₁ is R₂₀,] R is H, and m=1; [all geometric, optical, and stereoisomers thereof,] or a pharmaceutically acceptable acid addition salt thereof, in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier therefor.
